Lumos Diagnostics Holdings Limited (ASX:LDX)
Australia · Delayed Price · Currency is AUD 0.2600
-0.0100 (-3.70%)
Feb 5, 2026, 4:10 PM AEST
Lumos Diagnostics Holdings Company Description
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States.
The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19.
It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.
Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
Lumos Diagnostics Holdings Limited
| Country | Australia |
| Founded | 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| CEO | Douglas Ward |
Contact Details
Address: 2724 Loker Ave West Carlsbad, California 92010 United States | |
| Phone | 855 586 6739 |
| Website | lumosdiagnostics.com |
Stock Details
| Ticker Symbol | LDX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| ISIN Number | AU0000157091 |
| SIC Code | 3829 |
Key Executives
| Name | Position |
|---|---|
| Douglas Ward | Chief Executive Officer, MD and Director |
| Barrie Lambert | Chief Financial Officer |
| Anthony Favaloro | Vice President of Operations |
| Dr. Sacha Dopheide Ph.D. | Chief Technology Officer |
| Sarah Glubka | Vice President of Human Resources |
| Paul Kase | Senior Vice President of Commercial Operations |
| Tracy Weimar BA, MBA | Company Secretary |
| Annie Bell | Vice President of Medical Affairs |
| Amelia Stephens | Global Marketing and Awareness Consultant |